{"schema_version":"secwatch.filing_event.v1","accession":"0001999480-25-000075","form_type":"8-K","ticker":"ANRO","cik":"0001999480","company_name":"Alto Neuroscience, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.787961+00:00","generated_at":"2026-05-17T14:03:54.144912+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Alto Neuroscience Q2 net loss $17.7M; ALTO-207 acquisition expands TRD pipeline; data readouts ahead","bullets":["Net loss $17.7M in Q2 2025 vs $16.0M in Q2 2024; cash $148.1M expected to fund operations into 2028.","Acquired ALTO-207 (pramipexole/ondansetron) from Chase; Phase 2b in TRD planned by mid-2026.","ALTO-101 Phase 2 POC topline data for CIAS expected 2H 2025; ALTO-300 Phase 2b MDD data mid-2026.","ALTO-100 Phase 2b bipolar depression data expected 2H 2026; ALTO-203 showed positive pharmacodynamic results.","Appointed Raymond Sanchez, M.D., to Board; class structure reconstituted, committee assignments updated."],"urls":{"canonical":"https://secwatch.observer/filing/0001999480-25-000075","json":"https://secwatch.observer/filing/0001999480-25-000075.json","markdown":"https://secwatch.observer/filing/0001999480-25-000075.md","text":"https://secwatch.observer/filing/0001999480-25-000075.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000075/0001999480-25-000075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000075/alto-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:03:54.144912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}